Welcome to the UPF Digital Repository

COVID-19 incidence in patients with immunomediated inflammatory diseases: influence of immunosuppressant treatments

Show simple item record

dc.contributor.author Soldevila-Domenech, Natalia
dc.contributor.author Tío, Laura
dc.contributor.author Llorente Onaindia, Jone
dc.contributor.author Martín García, Elena, 1975-
dc.contributor.author Nebot Forcada, Pau
dc.contributor.author Torre Fornell, Rafael de la
dc.contributor.author Gurt, Alba
dc.contributor.author Maldonado, Rafael, 1961-
dc.contributor.author Monfort, Jordi
dc.contributor.author Covidmar Study Group
dc.date.accessioned 2021-02-15T06:48:11Z
dc.date.available 2021-02-15T06:48:11Z
dc.date.issued 2020
dc.identifier.citation Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group. COVID-19 incidence in patients with immunomediated inflammatory diseases: influence of immunosuppressant treatments. Front Pharmacol. 2020; 11:583260. DOI: 10.3389/fphar.2020.583260
dc.identifier.issn 1663-9812
dc.identifier.uri http://hdl.handle.net/10230/46471
dc.description.abstract The effect of immunosuppressant treatments on the incidence of coronavirus disease (COVID-19) remains largely unknown. We studied the association between the pre-exposure to disease-modifying antirheumatic drugs (DMARDs) that decrease immunological responses and the incidence of COVID-19 to explore the possible effects of these treatments in early manifestations of the disease. For this purpose, we performed a cross-sectional study including 2,494 patients with immunomediated inflammatory diseases (IMIDs) recruited at the outpatient Rheumatology, Dermatology and Gastroenterology services of Hospital del Mar. The primary outcome was the clinical diagnosis of COVID-19 performed by a physician at the hospital or at the primary care center, from the March 1-29, 2020. Multivariable Poisson regression models were fitted to estimate COVID-19 relative risk (RR) adjusted by comorbidities. We revealed that biological (RR = 0.46, CI 95% = 0.31-0.67) and synthetic (RR = 0.62, CI 95% = 0.43-0.91) DMARDs used in IMIDs diminished the incidence of COVID-19. Striking sex differences were revealed with anti-TNFα compounds (RR = 0.50, CI 95% = 0.33-0.75) with higher effects in women (RR = 0.33, CI 95% = 0.17-0.647). Treatment with low glucocorticoid doses also revealed sex differences decreasing the incidence of COVID-19 predominantly in women (RR = 0.72, CI 95% = 0.42-1.22). Our results report a decreased incidence of COVID-19 in patients receiving specific DMARDs with different immunodepressor mechanisms with striking sex differences. These results underline the interest of repurposing specific DMARDs for the possibility of minimizing the severity of disease progression in the early stages of COVID-19.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Front Pharmacol. 2020; 11:583260
dc.rights © 2020 Soldevila-Domenech, Tío, Llorente‐Onaindia, Martín‐García, Nebot, de la Torre, Gurt, Maldonado and Monfort. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title COVID-19 incidence in patients with immunomediated inflammatory diseases: influence of immunosuppressant treatments
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fphar.2020.583260
dc.subject.keyword Biological therapy
dc.subject.keyword Cross-sectional study
dc.subject.keyword Disease modifying antirheumatic drugs (DMARDs)
dc.subject.keyword Gender
dc.subject.keyword Glucocorticoids
dc.subject.keyword Relative risk
dc.subject.keyword Tumor necrosis factor inhibitor
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking